In a nutshell This study evaluated the effectiveness and safety of the combination of trifluridine-tipiracil (Lonsurf) and bevacizumab (Avastin) in patients with unresponsive (refractory) metastatic colorectal cancer (mCRC) in a real-world setting. The main finding was that trifluridine–tipiracil plus bevacizumab was safe and effective in...
Read More
In a nutshell This study evaluated the effectiveness of chemotherapy given before surgery (neoadjuvant chemotherapy; NAC) for the treatment of patients with colorectal cancer liver metastasis (CRLM) at high risk. The data showed that NAC improved the overall survival of these patients. Some background Colorectal cancer (CRC) is one of the most common...
Read More
In a nutshell This study evaluated the effectiveness and safety of robotic versus laparoscopic abdominoperineal resections (APRs) for the treatment of patients with low rectal cancer (RC). The data showed that robotic APRs significantly reduced surgical trauma and promoted recovery after surgery compared with laparoscopic APRs in these patients. Some...
Read More
In a nutshell This study evaluated the effectiveness and safety of microwave ablation (MWA) therapy for the treatment of lung metastases in patients with colorectal cancer (CRC). The data showed that MWA therapy might be a safe and effective option for these patients. Some background CRC is one of the most common types of cancer worldwide. Some...
Read More
In a nutshell This study evaluated the effectiveness and safery of administering modified (m) FOLFOXIRI (folinic acid, fluorouracil, irinotecan, oxaliplatin) chemotherapy with or without radiotherapy before surgery in patients with locally advanced rectal cancer (LARC). The results showed that this treatment was safe and improved survival without disease...
Read More
In a nutshell This study evaluated the effectiveness and safety of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab (Avastin) with or without atezolizumab (Tecentriq) on the outcomes of patients with metastatic (m) colorectal cancer (CRC). The study showed that adding atezolizumab to FOLFOXIRI plus...
Read More
In a nutshell This study evaluated the effectiveness and safety of transanal (ta) versus laparoscopic (lap) total mesorectal resection (TME) for the treatment of patients with stage I-III rectal cancer (RC). The data showed that experienced surgeons can safely perform taTME in these patients. Some background Rectal cancer (RC) is one of the most...
Read More
In a nutshell This study evaluated the effectiveness of transanal endoscopic microsurgery (TEM) for the treatment of early rectal cancer (RC) in patients over 60 years old with high surgical risk. The data showed that TEM is a reliable and effective treatment option in high-risk patients over 60 years old. Some background Rectal cancer (RC) is one of...
Read More
In a nutshell The study evaluated the effectiveness of massage therapy for chemotherapy-induced peripheral neuropathy (CPIN) in patients with breast and gastrointestinal (GI) cancer. The main finding of the study was that intensive massage therapy 3 times a week showed promising results in these patients. Some background There are many cancer...
Read More
In a nutshell This study evaluated the effectiveness and safety of adding oxaliplatin (Eloxatin; 3 months vs 6 months) to 6 months of fluoropyrimidine therapy such as 5-Fluorouracil (Adrucil) or capecitabine (Xeloda) as adjuvant (treatment after surgery) treatment in patients with stage II or III colon cancer. The data showed that adding 3 months of...
Read More
In a nutshell This study compared the effectiveness of TAS-102 (Lonsurf; trifluridine-tipiracil) versus regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that TAS-102 had better oncologic outcomes than regorafenib in these patients. Some background Colorectal cancer (CRC) is one of the...
Read More
In a nutshell This study evaluated the health-related quality of life (HR-QoL) outcomes of second-line chemotherapy combined with either bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with advanced colorectal cancer with wild-type KRAS. This study concluded that the HR-QoL outcomes were similar with both treatments in these...
Read More
